ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026
Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOmadacycline is a tetracycline antibiotic approved for the treatment of community-acquired bacterial pneumonia and possesses activity against pulmonary infections caused by Mycobacteroides abscessus (formerly Mycobacterium abscessus). Initial therapy for pulmonary M. abscessus disease often consists of a combination of intravenous agents, which may include intravenous omadacycline. The physical compatibility of omadacycline with other intravenous agents used in the treatment of pulmonary M. abscessus disease is unknown.
methodsPhysical compatibility of omadacycline 1 mg/mL was assessed via actual Y-site infusion with amikacin, azithromycin, cefoxitin, imipenem/cilastatin, and linezolid. Assessments of the triple-agent combinations of omadacycline with linezolid plus amikacin and imipenem/cilastatin plus amikacin were also performed. As needed, agents were reconstituted with sterile water for injection and diluted in 0.9% sodium chloride injection to typical clinical concentrations. Each combination was tested for compatibility using visual, laser light scattering, microscopy, pH, and turbidity assessments. Samples were taken from the start and end of a typical 30-minute omadacycline infusion and assessed immediately and again 2 hours after mixing. All experiments were performed in triplicate.
resultsNo physical incompatibility was demonstrated with any tested combination of agents with any method at any time point. Results were consistent across experiments.
conclusionAt clinical concentrations of agents used in the treatment of pulmonary M. abscessus disease, omadacycline appears to be physically compatible in dual-agent combinations in Y-site infusion with amikacin, azithromycin, cefoxitin, imipenem/cilastatin, and linezolid, as well as in triple combinations of omadacycline plus imipenem/cilastatin and amikacin and omadacycline plus linezolid and amikacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.